With the latest India deal, GSK is set to spend close to USD two billion in roughly a year to increase its holdings in two listed Indian companies, underscoring the British drugmaker's drive to deepen its footprint in emerging markets. (Agencies)
In February, GSK lifted its stake in its publicly-listed Indian consumer healthcare subsidiary, GlaxoSmithKline Consumer Healthcare Ltd, to 72.5 percent from 43.2 percent for USD 901 million.
The deals are the latest of several by GSK which is reducing its reliance on traditional prescription drug markets in Western economies where sales are slowing.
On Monday, GSK said it would buy up to 20.6 million shares of GlaxoSmithKline Pharmaceutical Ltd at 3,100 rupees a share, a premium of 26 percent over its closing market price on Friday. The company said that it planned to keep the Indian unit listed even after raising the stake.
As per Indian regulations, promoters of listed companies can hold up to a maximum 75 percent stake. If the promoter's shareholding rises beyond 75 percent, the company has to be de-listed from the bourse.
"For GSK this transaction will increase exposure to a strategically important market and for our Indian pharmaceuticals subsidiary's shareholders. We believe it offers a good liquidity opportunity at an attractive premium," David Redfern, chief strategy officer of GSK, said in a statement.
The transaction will be funded by GSK's existing cash and will be earnings neutral for the first year and accretive thereafter, the company said in a statement.
GSK's Indian pharmaceuticals unit makes drugs for various areas including respiratory, cardiovascular, oncology, anti-infectives and dermatology. The offer is likely to begin in February and the deal is being managed by HSBC.
With the latest India deal, GSK is set to spend close to USD two billion in roughly a year to increase its holdings in two listed Indian companies, underscoring the British drugmaker's drive to deepen its footprint in emerging markets.